Skip to main content
TipRanks
Go Ultimate75% OFF

Vectus Biosystems Limited (VBS) AI Stock Analysis

6 Followers
AU:VBS

Vectus Biosystems Limited

(ASX:VBS)

Select Model
Rating:42Neutral
Price Target:AUD 0.05â–¼(-9.43% Downside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance (zero revenue, ongoing operating losses, and persistent cash burn) and very bearish technical trends (price below all major moving averages with negative momentum). Valuation provides only a modest offset due to a very low P/E, but fundamentals reduce confidence in that signal.

Positive Factors
Positive equity and moderate leveragePositive equity and moderate leverage provide a more stable capital structure than the company had in earlier periods. This can preserve some financial flexibility over the next several months, although the benefit depends on the company controlling ongoing losses and cash use.
Negative Factors
Revenue has fallen to zeroThe collapse to zero revenue signals a severe loss of commercial momentum and leaves no current operating sales base from which to fund the business. Without a demonstrated recovery, this materially weakens visibility into sustainable growth and future operating scale.

Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)

-80%-60%-40%-20%0%20%40%AU:VBS-66.88%EWA+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 3.30M
Dividend Yield
―
Average Volume (3M)
51.16K
Price to Earnings (P/E)
1.8
Beta (1Y)
1.23
Revenue Growth
―
EPS Growth
―
Country
Australia
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Vectus Biosystems Limited Business Overview & Revenue Model

Company Description

Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs....

Vectus Biosystems Limited Financial Statement Overview

Summary

Overall financial quality is weak: revenue has fallen to zero in 2026 while operating losses persist and cash flow remains consistently negative (free cash flow -573k in 2026). The main offset is a stabilized balance sheet with positive equity (2.32m) and moderate leverage (debt 547k), but the 2026 net profit appears non-operating given negative operating cash flow.

Income Statement

26Negative

Balance Sheet

48Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue00478.18K1.14M1.35M1.30M
Gross Profit-4,597-4,597478.18K1.14M1.31M1.28M
EBITDA-1.36M-1.36M-1.69M-2.27M-3.19M-3.28M
Net Income1.56M1.56M-1.78M-2.34M-3.45M-3.99M
Balance Sheet
Total Assets3.82M3.82M782.66K2.03M4.63M3.94M
Cash, Cash Equivalents and Short-Term Investments3.52M3.52M250.99K808.97K2.95M1.28M
Total Debt546.66K546.66K200.00K28.93K70.21K6.90M
Total Liabilities1.50M1.50M1.04M539.26K1.11M8.36M
Stockholders Equity2.32M2.32M-256.62K1.49M3.52M-4.42M
Cash Flow
Free Cash Flow-573.39K-573.40K-830.09K-2.10M-2.37M-4.46M
Operating Cash Flow-573.39K-573.39K-830.09K-2.03M-2.35M-4.44M
Investing Cash Flow00101.03K-67.90K-17.13K-21.00K
Financing Cash Flow1.04M1.04M171.07K-41.28K4.04M-34.55K

Vectus Biosystems Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.05

Price Trends

50DMA0.10Negative
100DMA0.13Negative
200DMA0.13Negative

Market Momentum

MACD-0.01Positive
RSI17.78Positive
STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.10, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 17.78 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:VBS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:ACRAU:ACR52NeutralAUD 5.82M-6.79-45.29%―290.25%92.05%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:TRPAU:TRP47NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:OCCAU:OCC44NeutralAUD 155.26M-10.75-36.83%―51.07%-47.63%
AU:VBSAU:VBS42NeutralAUD 3.30M1.84206.11%―――
AU:CMBAU:CMB39UnderperformAUD 10.60M-1.43-247.44%―-4.24%33.39%
AU:BOTAU:BOT38UnderperformAUD 22.10M-0.25-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%AU:VBSAU:ACRAU:OCCAU:TRPAU:CMBAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:VBS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:VBSVectus Biosystems Limited0.05-0.15-73.50%
AU:ACRAcrux Limited0.01-0.01-37.50%
AU:OCCOrthocell Ltd0.57-0.41-41.84%
AU:TRPTissue Repair Ltd0.11-0.18-62.07%
AU:CMBRegeneus Ltd.0.36-0.15-29.41%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.00%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Issues 7.9 Million Unquoted Options in New Class

Oct 30, 2026

Vectus Biosystems Limited has notified the market of the issue of 7,910,000 unquoted options, each with an exercise price of $0.20 and an expiry date of 30 October 2028. These options constitute a new class of securities that are not quoted and are n...

Vectus Biosystems Secures FDA Pre-IND Pathway for IPF Drug as Cash Position Tightens

Oct 29, 2026

Vectus Biosystems reported quarterly progress centred on advancing its lead antifibrotic candidate VB0004 for idiopathic pulmonary fibrosis in the U.S. regulatory system. The company highlighted that the FDA has granted its request for a pre-IND Type...

Vectus Biosystems Wins Unanimous Shareholder Backing at AGM

Oct 28, 2026

Vectus Biosystems Limited reported that all resolutions put to shareholders at its Annual General Meeting on 28 October 2026 were passed on a poll, demonstrating unanimous proxy support for each item. The meeting endorsed the re-election of director...

Vectus Biosystems sharpens fibrosis focus as VB0004 advances and partnering strategy gains traction

Oct 27, 2026

Vectus Biosystems reported a year of strategic refocusing around the development and commercialisation of its antifibrotic drug library, with lead compound VB0004 progressing on the back of a Phase Ia trial that showed it to be safe and well tolerate...

Vectus wins FDA pre-IND green light for VB0004 in IPF

Sep 29, 2026

Vectus Biosystems has secured a pre-Investigational New Drug Type B meeting with the U.S. Food and Drug Administration for its lead antifibrotic candidate VB0004 in idiopathic pulmonary fibrosis. The company, working with Cardinal Health Regulatory S...

Vectus Biosystems sets virtual AGM to ratify capital raising and board re‑election

Sep 25, 2026

Vectus Biosystems Limited has called its 2026 Annual General Meeting for 28 October, to be held virtually via Zoom, with shareholders instructed to access the webcast using details provided by the company’s share registrar, Computershare. The AGM wil...

Vectus Biosystems Updates Corporate Governance Framework for 2026

Sep 18, 2026

Vectus Biosystems has released its latest corporate governance statement, outlining how it applies the ASX Corporate Governance Council’s principles for the period from 1 July 2025 to 30 June 2026. The company notes that while it aims to comply with...

Vectus Biosystems Releases 2026 Consolidated Annual Report

Sep 18, 2026

Vectus Biosystems Limited has released its 2026 annual financial report, covering the consolidated entity and detailing financial statements, notes and the Directors’ declaration in Australian dollars. The report, authorised by the Board of Directors...

Vectus Biosystems Sets Date and Process for 2026 Virtual AGM

Sep 9, 2026

Vectus Biosystems has scheduled its 2026 Annual General Meeting for 11:00am Sydney time on 28 October 2026, to be held as a fully virtual event via Zoom for shareholders. The company has also opened the window for director nominations, which must be...

Vectus Biosystems Director Converts Options into Shares, Boosting Equity Stake

Sep 4, 2026

Vectus Biosystems Limited has reported a change in director Maurie Stang’s interests, with the exercise of 316,000 zero-priced options into fully paid ordinary shares. Following this transaction on 2 September 2026, Stang’s holdings now include the n...

Vectus Biosystems Issues New Shares to Non-Executive Director Under Incentive Plan

Sep 2, 2026

Vectus Biosystems Limited has issued 316,000 new fully paid ordinary shares to Deputy Chairman and Non-Executive Director Maurie Stang, following the exercise of options granted under the company’s Employee Incentive Plan as payment for director fees...

Vectus Biosystems Seeks ASX Quotation for 316,000 New Shares

Sep 2, 2026

Vectus Biosystems Limited has applied for quotation on the ASX of 316,000 new ordinary fully paid shares under its existing ticker VBS. The securities, issued on September 2, 2026, arise from the exercise or conversion of options or other convertible...

Vectus Biosystems Sharpens Strategy as VB0004 Takes Centre Stage

Aug 30, 2026

Vectus Biosystems has entered a new phase of development in 2025-26, appointing Dr Tara Speranza as chief executive and chief technology officer to sharpen its drug development and commercial strategy. Her appointment is intended to strengthen intern...

Vectus Biosystems Swings to Profit as Revenue Soars and Balance Sheet Strengthens

Aug 30, 2026

Vectus Biosystems Limited reported a sharp turnaround for the year to 30 June 2026, with revenues from ordinary activities surging 478.7% to $2.77 million and a consolidated profit after tax of $1.56 million, compared with a restated loss of $1.86 mi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026